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SUPPLEMENTARY NOTES
ABSTRACT
Prostate cancer is the most common diagnosed and second leading cause of epithelial cancerrelated death in men. Small cell neuroendocrine carcinoma (SCNC) accounts for only 1% of diagnosed prostate cancers prior to aggressive therapy. However, after administration of aggressive therapy, tumor resistance is inevitable resulting in the acquisition of SCNC tumors in well over 20% of patients. SCNC tumors are highly aggressive, metastasize readily, and often lead to death of the patient within months after diagnosis. Tyrosine kinases represent an untapped area for therapy in the stratification of SCNC patients. We observed that RET tyrosine kinase is heightened at the mRNA and protein level in SCNC tissues and neuroendocrine cell lines when compared to adenocarcinoma. RET expression and related neuroendocrine markers were upregulated in a model of neuroendocrine differentiation and RET mutations resulted in initiation of prostate cancer. Future work will continue to define the role of RET in prostate cancer.
INTRODUCTION
Prostate cancer is the most common diagnosed and second leading cause of epithelial cancer-related death in men 1 . Therefore, much is to be learned about the growth and resistance of epithelial cancer cells to current therapeutics. Small cell neuroendocrine carcinoma (SCNC) accounts for only 1% of diagnosed prostate cancers prior to aggressive therapy 2 . However, after administration of aggressive therapy, tumor resistance is inevitable resulting in the acquisition of SCNC tumors in well over 20% of patients. SCNC tumors are highly aggressive, metastasize readily, and often lead to death of the patient within months after diagnosis. The mechanism for the increase in the SCNC component of prostate cancer after aggressive therapy is unclear and therapies to treat this variant form of the disease are severely lacking. One family of proteins thought to promote cancer growth and resistance to aggressive therapy are the tyrosine kinases. Tyrosine kinase activity has been shown to play a role in prostate cancer, but targeting these same molecules clinically has not been very successful 3 . In this proposal, our objective was to evaluate a novel tyrosine kinase target, RET, in men with SCNC who have become resistant to current treatments. This new target will provide a novel mechanism and treatment strategy that will benefit a growing population of men suffering from metastatic SCNC. Further, the proposed study will help to advance the field of prostate cancer research by providing greater insight into better treatment options and strategies for administration of specific, targeted inhibitors in patients with SCNC.
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What was accomplished under these goals?
For Aim 1, we were able to perform immunohistochemistry of RET protein on CRPC tissue microarrays consisting of normal prostate tissue, prostate cancer, and small cell neuroendocrine carcinoma (SCNC) and adenocarcinoma (AdCa). We found that total RET immunostaining was prominent in subsets of patients with both SCNC and AdCa, but lower in normal prostate and prostate cancer tissues (Figure 1A-D) . The frequency of RET IHC staining was about 50% of the patients analyzed. We also analyzed RET protein via western blot in a large panel of prostate cancer cell lines. Strikingly, RET protein was only observed in the cell lines with a small cell or neuroendocrine phenotype and not cell lines with the adenocarcinoma phenotype ( Figure 1E ). We are not sure why the discrepancy exists between IHC staining and western blot as it pertains to RET kinase levels between SCNC and AdCa. We are still investigating why this is the case. One possibility is that total RET may not be expressed at different levels between SCNC and AdCa suggesting that we need to look at the phosphorylation levels of RET. We have attempted IHC using an antibody that recognizes RET phosphorylation but with little luck to date as the phospho-site antibody does not work very well. Overall, this data suggests that RET protein is indeed present in CRPC and possible enriched in SCNC based on cell line data with the neuroendocrine phenotype. We will need to assess more tissues and eventually generate a phosphosite specific antibody that recognizes RET phosphorylation to measure RET activity.
For Aim 2, we assessed the expression of RET and other neuroendocrine markers at the mRNA level to determine if they are correlated upon androgen withdrawal. Previous studies have shown that LNCaP cells grown in charcoal stripped media (mimics androgen withdrawal) will develop neuroendocrine-like differentiation 4 . We used this model to assess the levels of RET transcript after growing LNCaP cells in charcoal stripped media. By Day 6 and Day 9, we observed noticeable morphology changes of LNCaP cells (Figure 2A-D) as well as distinct changes in RET mRNA and the neuroendocrine markers synaptophysin and chromogranin A (Figure 2E-G) . These preliminary findings suggest that RET kinase increases expression when cells undergo neuroendocrine differentiation after androgen withdrawal. Next, we generated lentiviral vectors against wildtype (WT) RET, and 2 different RET mutants that render the kinase constitutively activated (RET C634W and RET M918T) ( Figure  3A) . All three vectors express RET protein at a high level and were used for both in vitro and in vivo studies (Aim 3). To test the capability of RET kinase to transdifferentiate in vitro, we transduced WT RET and RET mutants into our LNCaP cell line model and monitored the cellular morphology over time (Figure 3B-G) . Androgen withdrawal did induce the neuroendocrine phenotype ( Figure 3E-G) , but the addition of RET mutants did not exacerbate this phenotype in either normal growth conditions (Figure 3B-D) or in androgen depleted conditions (Figure 3E-G) . Therefore, the potency of androgen withdrawal may override any effects observed by exogenous addition of the RET gene.
For Aim 3, we assessed the capability of WT RET or mutant RET to aid in prostate cancer initiation using the primary human tissue recombination model. Two RET mutants (RET C634W and RET M918T) were chosen that render the kinase constitutively active ( Figure 4A, red arrows) . Primary prostate basal cells were transduced with WT RET, RET C634W, or RET M918T alone or in combination with other oncogenes (Figure 4B) . WT RET did not produce a tumor phenotype alone or in combination with an activated AKT or N-MYC. Interestingly, both RET mutants synergized with N-MYC to generate a large tumor although this phenotype primarily consisted of squamous differentiation ( Figure 5B , C, bottom panels and Figure 6A ). This tumor expressed RET protein ( Figure 6B ) as well as markers of luminal cells with CK8 expression and low levels of androgen receptor (AR) (Figure C, F) . In addition, basal cell markers were also present as evidenced by p63 and CK5 (Figure 6D, E) . In all, the capability of RET mutants to synergize with N-MYC in human prostate cancer models is exciting and worth pursuing further. We will need to determine how best to generate an adenocarcinoma phenotype prior to testing the capability of RET protein to contribute to castration resistance in these models.
What opportunities for training and professional development has the project provided? Nothing to report.
How were the results disseminated to communities of interest?
Nothing to report.
What do you plan to do during the next reporting period to accomplish the goals?
IMPACT What was the impact on the development of the principal discipline(s) of the project?
Therapeutic targeting of tyrosine kinases in late stage prostate cancer are still underdeveloped. We have begun investigation into one particular tyrosine kinase, RET, and observed that RET mRNA and protein are heightened in CRPC and SCNC.
What was the impact on other disciplines?
What was the impact on technology transfer?
What was the impact on society beyond science and technology?
CHANGES/PROBLEMS Changes in approach and reasons for change.
Actual or anticipated problems or delays and actions or plans to resolve them.
We are still working out conditions to get an antibody to recognize phosphorylated RET kinase at the western blot and IHC level in our models. So far we have not had any luck to get this to stain appropriately and are currently making an antibody to phosphorylated RET for our own use. Any studies proposing to evaluate RET phosphorylation have not been able to be completed because of this technical hurdle.
We did not evaluate the levels of RET mRNA in different populations of primary human cells in Aim 2 because we could not isolate sufficient numbers of neuroendocrine cells for our study. Because of this limitation we determined it would be better to test whether RET and other neuroendocrine markers' mRNA was altered in established cell line models such as LNCaP.
In addition, we have not been able to perform castration experiments in Aim 3 yet because the tumors that develop from RET kinase are primarily squamous, not adenocarcinoma. We are currently investigating how to develop more adenocarcinoma-like tumors prior to castration which will allow us to more accurately assess RET function during castration as well as neuroendocrine differentiation during this process. One approach is to sort out the luminal like cells from the tumors and re-transplant back into mice. This has been down previously in our lab and provides a viable option to test 5 . One explanation for why WT RET did not generate a tumor phenotype is because the endogenous ligand is not present. We are currently in the process of re-evaluating the capability of WT RET to transduce primary human basal cells with the presence of the ligand GDNF. These experiments are underway.
More recently, focus has turned to in hibition of more downstream effector targets such as mTOR. Due to a wide array of signaling inputs to mTOR, mTOR inhibitors can more broadly be applied to cancers not dependent on the PI3K/AKT pathway, in creasing the utility of these inhibitors over PI3K and AKT agents. Allosteric mTOR inhibitors, such as everolimus, have not performed well in clinical trials for pros tate cancer (11), but mTOR active site inhibitors, such as MLN0128 (INK128), outperformed everolimus in preclinical models of prostate cancer (12) . The in creased efficacy of mTOR active site inhibitors is attributed to targeting ever olimus resistant substrates such as 4EBP1, as well as completely blocking both mTOR com plexes (mTORC1 and C2) and eliminating AKT activation via feedback from S6 kinase (S6K) (13) .
Where are we now in the field of PI3K pathway inhibitors for treatment of prostate cancer? There are several PI3K agents avail able, but to date, the clinical benefit has been limited if these compounds are used as a single agent. The lack of clinical benefit could be due to the activation of alternative signaling pathways such as AR or other kinase pathways. Indeed, development of CRPC may be due to the activation of the PI3K pathway during AR inhibitor therapy, suggesting cross talk between these two pathways (14, 15) . As such, combination therapies targeting both the PI3K/AKT pathway and AR are begin ning to be tested clinically (16) . The de velopment of combination strategies will be imperative to achieve the goal of signifi cantly improving survival in patients suf fering from cancer. The central dilemma seems to be in choosing the right combina tions. In the PI3K pathway, several combi nation strategies are currently being or will be tested including PI3K/AKT in hibitors combined with mTOR inhibitors (vertical treatment approach) and PI3K/ AKT/mTOR inhibitors with AR inhibi tors (horizontal treatment approach) (Fig. 1) . Hence, it would be worthwhile to investigate the effects of combination therapies using ISA 2011B with an AR inhibitor, or other pathway inhibitors, in Metastatic castration resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. The need to identify new actionable targets in metastatic CRPC is crucial as we begin to examine the resistance mechanisms related to androgen withdrawal. Although multiple metastases from the same patient share similar copy number, mutational status, ETS rearrangements, and methylation patterns supporting their clonal origins, it is not known whether actionable targets such as kinases are also similarly expressed and activated in anatomically distinct metastatic lesions of the same patient. We evaluated active kinases using phosphopeptide enrichment and quantitative mass spectrometry to identify therapeutic kinase networks in metastatic CRPC obtained at rapid autopsy. We identified distinct phosphopeptide patterns in metastatic tissues compared to naive primary prostate tissue and prostate cancer cell line-derived xenografts. Evaluation of metastatic CRPC samples for kinase targets revealed SRC, EGFR, RET, ALK, and MAPK1/3 and other activities while exhibiting intrapatient similarity and interpatient heterogeneity. Computational approaches merging metastatic CRPC transcriptomic and phosphoproteomic datasets revealed a highly interconnected network of activated kinases with transcriptional regulators. Interestingly, these kinase activities are not a result of mutation but rather pathway activation within the tumors themselves. In all, this suggests that individualized therapy targeting non-mutated kinases with clinical kinase inhibitors may be an effective strategy in the treatment of metastatic CRPC.
